Highly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies

Biomedical Chromatography 2021 November 5 [Link] Eleonora W J van Ewijk-Beneken Kolmer, Marga J A Teulen, Rene J Boosman, Nikki de Rouw, Jacobus A Burgers, Rob Ter Heine Abstract Pemetrexed is an antifolate drug approved for the treatment of non-small-cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may…

Read More

The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma

International Journal of Molecular Sciences 2021 July 10 [Link] Li Yuan, Boshu Sun, Liangliang Xu, Limin Chen, Wenbin Ou Abstract SET domain bifurcated 1 (SETDB1) is a histone H3 lysine 9 (H3K9) methyltransferase that exerts important effects on epigenetic gene regulation. SETDB1 complexes (SETDB1-KRAB-KAP1, SETDB1-DNMT3A, SETDB1-PML, SETDB1-ATF7IP-MBD1) play crucial roles in the processes of histone…

Read More

An EBC/Plasma miRNA Signature Discriminates Lung Adenocarcinomas From Pleural Mesothelioma and Healthy Controls

Frontiers in Oncology 2021 June 15 [Link] Alice Faversani, Chiara Favero, Laura Dioni, Angela Cecilia Pesatori, Valentina Bollati, Matteo Montoli, Valeria Musso, Andrea Terrasi, Nicola Fusco, Mario Nosotti, Valentina Vaira, Alessandro Palleschi Abstract Background: Despite significant improvement in screening programs for cancers of the respiratory district, especially in at-risk subjects, early disease detection is still…

Read More

Controversies in the role of radiotherapy in pleural mesothelioma

Translational Lung Cancer Research 2021 April [Link] Gerard G Hanna, Thomas John, David L Ball Abstract Malignant pleural mesothelioma is an uncommon thoracic cancer with a relatively poor outcome, which has only seen modest improvements when compared to non-small cell lung cancer. The mainstays of treatment have been surgery and systemic therapy, with radiation reserved…

Read More

Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma

The American Journal of Surgical Pathology 2021 March 29 [Link] Julia R Naso, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract The separation of malignant mesothelioma from non-small cell lung carcinomas can be a difficult problem. Sex-determining region Y box 6 (SOX6) and disabled homolog 2 (DAB2) have recently been proposed as sensitive/specific markers of…

Read More

High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer

ERJ Open Research 2021 March 22 [Link] Lars Hagmeyer, Stephan Schäfer, Marianne Engels, Anja Pietzke-Calcagnile, Marcel Treml, Simon-Dominik Herkenrath, Matthias Heldwein, Khosro Hekmat, Sandhya Matthes, Andreas Scheel, Jürgen Wolf, Reinhard Büttner, Winfried Randerath Abstract Background: Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) immune checkpoint inhibitors have been approved for monotherapy…

Read More

The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

Journal of Thoracic Disease 2021 February [Link] Camila M Baldavira, Juliana Machado-Rugolo, Tabatha G Prieto, Daniel R Bastos, Marcelo Balancin, Alexandre M Ab’Saber, Lygia B Yaegashi, Paola C Souza, Cecilia Farhat, Teresa Y Takagaki, Maria Ap Nagai, Vera L Capelozzi Abstract Background: Pleckstrin homology domain family A (PHLDA) genes play important roles in cancer cellular…

Read More

Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types

The British Journal of Radiology 2021 February 5 [Link] Sarah Denzler, Diem Vuong, Marta Bogowicz, Matea Pavic, Thomas Frauenfelder, Sandra Thierstein, Eric Innocents Eboulet, Britta Maurer, Janine Schniering, Hubert Szymon Gabryś, Isabelle Schmitt-Opitz, Miklos Pless, Robert Foerster, Matthias Guckenberger, Stephanie Tanadini-Lang Abstract Objectives: In this study, we aimed to assess the impact of different CT…

Read More

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet 2021 January 21 [Link] Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman Abstract Background: Approved systemic treatments…

Read More

The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma

American Journal of Cancer Research 2020 December 1 [Link] Ayumi Kaneda, Toshihiro Seike, Tomohiro Danjo, Takahiro Nakajima, Nobumasa Otsubo, Daisuke Yamaguchi, Yoshiro Tsuji, Kaori Hamaguchi, Mai Yasunaga, Yoichi Nishiya, Michihiko Suzuki, Jun-Ichi Saito, Rie Yatsunami, Satoshi Nakamura, Yoshitaka Sekido, Kiyotoshi Mori Abstract The Hippo signaling pathway regulates cell fate and organ development. In the Hippo…

Read More